Andrea Lobo, PhD, science writer —

First Wave BioPharma has completed patient screening for the Phase 2 SPAN clinical trial of a new formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The trial (NCT05719311) will be conducted at three sites in Florida, Illinois, and Nevada, and include…

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to children with cystic fibrosis (CF) ages 2 to 5, who have at least one F508del mutation in the CFTR gene or a mutation that responds to Trikafta in laboratory studies.

SPRIM Global Investments (SGI) has committed $4.5 million to initiate Spexis’ Phase 3 COPILOT clinical trial to test the antibiotic ColiFin in people with cystic fibrosis (CF) who have chronic Pseudomonas aeruginosa lung infections. The trial will test once or twice daily dosing of ColiFin (inhaled colistimethate sodium),…

The Cystic Fibrosis Foundation (CFF) is investing up to $15.5 million in Anagram Therapeutics to conduct early-stage trials of a new oral enzyme replacement therapy. The company is planning to start a Phase 1 clinical trial this summer. The therapy would let people with cystic fibrosis (CF)…

Pulmonary exacerbations in children with cystic fibrosis (CF) caused by multiple bacteria (polymicrobial) are generally treated with antibiotics that cover all the bacteria detected, a study reported. Whether this strategy is associated with better clinical outcomes than using antibiotics that cover only some of the detected bacteria remains to…

An exclusive telehealth care model used during the COVID-19 pandemic was associated with a decrease in pulmonary function in Australian children with cystic fibrosis (CF). “It is likely that telehealth based care should complement, rather than replace in person assessment,” according to the researchers. “Further work is needed to…

Neither exercise nor nutritional interventions were found to affect the microbial population — typically an underlying cause of lung function decline and disease progression in cystic fibrosis (CF) — in the lung and gut of people with CF, a study in Germany shows. That microbial population remained stable despite…

A Phase 2 clinical trial of an optimized formulation of adrulipase, a yeast-derived enzyme to treat exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis (CF), has screened its first patient. First Wave BioPharma, the therapy’s developer, anticipates dosing to start soon, with top-line results expected by mid-year.

A Phase 1 trial of ARCT-032, an inhaled experimental treatment for cystic fibrosis (CF), has been cleared to start in New Zealand. Developed by Arcturus Therapeutics, ARCT-032 contains the messenger RNA (mRNA) that provides instructions for lung cells to produce the CFTR protein, restoring its activity. Mutations in…

A higher body mass index (BMI) and recent exposure to certain antibiotics are risk factors for asymptomatic intestinal colonization with Clostridioides difficile in children with cystic fibrosis (CF), a new study suggests. The study, “Prevalence, Risk Factors, and Sequelae of Asymptomatic Clostridioides difficile Colonization in Children with Cystic…